Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
IBO
Upturn stock ratingUpturn stock rating

Impact BioMedical, Inc. (IBO)

Upturn stock ratingUpturn stock rating
$0.57
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: IBO (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

0 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

Analysis of Past Performance

Type Stock
Historic Profit 0%
Avg. Invested days 0
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 9.09M USD
Price to earnings Ratio -
1Y Target Price -
Price to earnings Ratio -
1Y Target Price -
Volume (30-day avg) -
Beta -
52 Weeks Range 0.36 - 6.17
Updated Date 06/28/2025
52 Weeks Range 0.36 - 6.17
Updated Date 06/28/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.07

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -7.06%
Return on Equity (TTM) -147.03%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 16971229
Price to Sales(TTM) -
Enterprise Value 16971229
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 4.72
Shares Outstanding 12085400
Shares Floating 11638131
Shares Outstanding 12085400
Shares Floating 11638131
Percent Insiders 39.26
Percent Institutions 3.19

ai summary icon Upturn AI SWOT

Impact BioMedical, Inc.

stock logo

Company Overview

overview logo History and Background

Impact BioMedical, Inc. is a biopharmaceutical company focused on the development and commercialization of novel therapeutics. Founded in 2011, the company's focus shifted towards creating innovative solutions in infectious disease and cancer. Key milestones include several clinical trials and partnerships.

business area logo Core Business Areas

  • Infectious Disease Therapeutics: Develops novel antiviral and antibacterial therapies to combat emerging infectious diseases.
  • Oncology Therapeutics: Focuses on developing targeted therapies and immunotherapies for various cancers.

leadership logo Leadership and Structure

The company is led by a team of experienced pharmaceutical executives and scientists. The organizational structure comprises research and development, clinical operations, and commercial divisions.

Top Products and Market Share

overview logo Key Offerings

  • Equivir (viral infection treatment): Equivir is an antiviral drug targeting a broad spectrum of viral infections. The company has not made available any real time market share data or revenue. Competitors: Gilead Sciences, Roche.
  • Proleukin (cancer treatment): Proleukin is an immunotherapy drug designed to enhance the body's immune response to cancer cells. The company has not made available any real time market share data or revenue. Competitors: Bristol Myers Squibb, Merck.

Market Dynamics

industry overview logo Industry Overview

The biopharmaceutical industry is characterized by high R&D costs, stringent regulatory requirements, and significant competition. Emerging markets and technological advancements are driving growth.

Positioning

Impact BioMedical, Inc. is positioned as an innovator in infectious disease and oncology therapeutics, leveraging proprietary technologies and strategic partnerships to gain a competitive edge.

Total Addressable Market (TAM)

The global pharmaceuticals market is estimated to be over $1.4 trillion. Impact BioMedical, Inc. is positioning itself in areas like targeted cancer therapies and antiviral medications, seeking to capture a small but growing segment of the TAM.

Upturn SWOT Analysis

Strengths

  • Innovative technology platform
  • Strong intellectual property portfolio
  • Experienced management team
  • Strategic partnerships

Weaknesses

  • Limited financial resources
  • Dependence on key personnel
  • Regulatory risks
  • Competition from larger pharmaceutical companies

Opportunities

  • Expanding into new therapeutic areas
  • Collaborating with academic institutions
  • Acquiring complementary technologies
  • Securing government funding

Threats

  • Patent expirations
  • Generic competition
  • Adverse clinical trial results
  • Changes in healthcare regulations

Competitors and Market Share

competitor logo Key Competitors

  • GILD
  • MRK
  • BMY
  • RHHBY

Competitive Landscape

Impact BioMedical, Inc. faces intense competition from established pharmaceutical giants. Its success depends on demonstrating superior efficacy and safety profiles for its drug candidates.

Growth Trajectory and Initiatives

Historical Growth: Due to the company's private status, historical growth data is limited.

Future Projections: Future growth projections are contingent upon successful clinical trials and regulatory approvals. Analyst estimates unavailable.

Recent Initiatives: Recent initiatives include the advancement of clinical trials for lead drug candidates and the forging of new strategic alliances.

Summary

Impact BioMedical, Inc. is a small biopharmaceutical firm with a focus on innovative therapies for infectious diseases and cancer. It holds promising technology and partnerships, but its growth is challenged by limited financial resources and significant regulatory hurdles. The company must successfully navigate these challenges to achieve its potential, which depends on positive clinical trials and commercialization efforts. Success is dependent on its intellectual property portfolio and efficacy of lead drug candidates. Future growth is dependent on funding or strategic partnerships.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company Website
  • SEC Filings (where available)
  • Industry Reports
  • Analyst Reports (where available)

Disclaimers:

This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice. The company's actual performance may differ materially from the information provided. Market share data can be estimated and may not always be precise.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Impact BioMedical, Inc.

Exchange NYSE MKT
Headquaters Houston, TX, United States
IPO Launch date 2024-09-16
Chairman & CEO Mr. Frank D. Heuszel Esq., J.D.
Sector Healthcare
Industry Biotechnology
Full time employees 2
Full time employees 2

Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use in as health supplements and medications. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas.